IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

Application of: Tan, J. et al. Confirmation No.: 2636

Serial No.: 10/694,634 Art Unit: 1633

Filed: October 27, 2003 Examiner: Popa, Ileana

For: METHODS AND COMPOUNDS FOR Attorney Docket No.: 12062.105020

DISRUPTION OF CD40/CD40L SIGNALING IN THE TREATMENT OF ALZHEIMER'S DISEASE

AMENDMENT UNDER 37 C.F.R. § 1.116

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the final Office Action mailed August 8, 2007 ("the Aug. 8 Office Action") please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith (i) a Request for Continued Examination ("RCE") containing authorization for payment of the appropriate fee; (ii) a Petition of Extension of Time for three (3) months for responding to the Office Action, from November 8, 2007 up to and including February 8, 2008; and (iii) an Amendment Fee Transmittal Sheet.

It is believed that there is no fee required for the filing of this response other than those authorized in the RCE and the Petition for Extension of Time submitted concurrently herewith; however, in the event that any additional fee is required, please charge King & Spalding Deposit Account No. 50-3732, order number 12062.105020.

Applicants' Statement of Substance of Interview begins on page 2 of this paper

Amendments to the Claims are reflected in the Listing of Claims, which begin on page 3 of this paper.

Remarks begin on page 7 of this paper.